JP2002544207A - 2,2-Dimethyl-1,3-dioxane intermediate salt and method for producing the same - Google Patents
2,2-Dimethyl-1,3-dioxane intermediate salt and method for producing the sameInfo
- Publication number
- JP2002544207A JP2002544207A JP2000617201A JP2000617201A JP2002544207A JP 2002544207 A JP2002544207 A JP 2002544207A JP 2000617201 A JP2000617201 A JP 2000617201A JP 2000617201 A JP2000617201 A JP 2000617201A JP 2002544207 A JP2002544207 A JP 2002544207A
- Authority
- JP
- Japan
- Prior art keywords
- acid
- dimethyl
- dioxane
- ethyl
- general formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000003839 salts Chemical class 0.000 title claims abstract description 19
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 8
- RPLSBADGISFNSI-UHFFFAOYSA-N 2,2-dimethyl-1,3-dioxane Chemical compound CC1(C)OCCCO1 RPLSBADGISFNSI-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 32
- HWSHVKNLMBMKSR-GHMZBOCLSA-N tert-butyl 2-[(4r,6r)-6-(2-aminoethyl)-2,2-dimethyl-1,3-dioxan-4-yl]acetate Chemical compound CC(C)(C)OC(=O)C[C@H]1C[C@@H](CCN)OC(C)(C)O1 HWSHVKNLMBMKSR-GHMZBOCLSA-N 0.000 claims abstract description 20
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 45
- 238000000034 method Methods 0.000 claims description 27
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 21
- 239000000203 mixture Substances 0.000 claims description 19
- 150000007524 organic acids Chemical class 0.000 claims description 13
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 claims description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 12
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 12
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 11
- 239000002253 acid Substances 0.000 claims description 11
- -1 aliphatic monocarboxylic acid Chemical class 0.000 claims description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 9
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 9
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 9
- RBBOWEDMXHTEPA-UHFFFAOYSA-N hexane;toluene Chemical compound CCCCCC.CC1=CC=CC=C1 RBBOWEDMXHTEPA-UHFFFAOYSA-N 0.000 claims description 8
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 7
- 238000006243 chemical reaction Methods 0.000 claims description 7
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 claims description 6
- ZEYHEAKUIGZSGI-UHFFFAOYSA-N 4-methoxybenzoic acid Chemical compound COC1=CC=C(C(O)=O)C=C1 ZEYHEAKUIGZSGI-UHFFFAOYSA-N 0.000 claims description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 6
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 6
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 6
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 6
- JBDSSBMEKXHSJF-UHFFFAOYSA-N cyclopentanecarboxylic acid Chemical compound OC(=O)C1CCCC1 JBDSSBMEKXHSJF-UHFFFAOYSA-N 0.000 claims description 6
- 239000003960 organic solvent Substances 0.000 claims description 6
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 claims description 6
- KWHDXJHBFYQOTK-UHFFFAOYSA-N heptane;toluene Chemical compound CCCCCCC.CC1=CC=CC=C1 KWHDXJHBFYQOTK-UHFFFAOYSA-N 0.000 claims description 5
- GPSDUZXPYCFOSQ-UHFFFAOYSA-N m-toluic acid Chemical compound CC1=CC=CC(C(O)=O)=C1 GPSDUZXPYCFOSQ-UHFFFAOYSA-N 0.000 claims description 5
- 239000012429 reaction media Substances 0.000 claims description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 4
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 claims description 4
- 229940092714 benzenesulfonic acid Drugs 0.000 claims description 4
- 239000001530 fumaric acid Substances 0.000 claims description 4
- 235000006408 oxalic acid Nutrition 0.000 claims description 4
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 3
- XYHKNCXZYYTLRG-UHFFFAOYSA-N 1h-imidazole-2-carbaldehyde Chemical compound O=CC1=NC=CN1 XYHKNCXZYYTLRG-UHFFFAOYSA-N 0.000 claims description 3
- GWYFCOCPABKNJV-UHFFFAOYSA-M 3-Methylbutanoic acid Natural products CC(C)CC([O-])=O GWYFCOCPABKNJV-UHFFFAOYSA-M 0.000 claims description 3
- PXACTUVBBMDKRW-UHFFFAOYSA-N 4-bromobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(Br)C=C1 PXACTUVBBMDKRW-UHFFFAOYSA-N 0.000 claims description 3
- TUXYZHVUPGXXQG-UHFFFAOYSA-N 4-bromobenzoic acid Chemical compound OC(=O)C1=CC=C(Br)C=C1 TUXYZHVUPGXXQG-UHFFFAOYSA-N 0.000 claims description 3
- KDVYCTOWXSLNNI-UHFFFAOYSA-N 4-t-Butylbenzoic acid Chemical compound CC(C)(C)C1=CC=C(C(O)=O)C=C1 KDVYCTOWXSLNNI-UHFFFAOYSA-N 0.000 claims description 3
- 239000005711 Benzoic acid Substances 0.000 claims description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 3
- 125000001931 aliphatic group Chemical group 0.000 claims description 3
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 3
- 235000010233 benzoic acid Nutrition 0.000 claims description 3
- GWYFCOCPABKNJV-UHFFFAOYSA-N beta-methyl-butyric acid Natural products CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 claims description 3
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims description 3
- TXWOGHSRPAYOML-UHFFFAOYSA-N cyclobutanecarboxylic acid Chemical compound OC(=O)C1CCC1 TXWOGHSRPAYOML-UHFFFAOYSA-N 0.000 claims description 3
- YMGUBTXCNDTFJI-UHFFFAOYSA-N cyclopropanecarboxylic acid Chemical compound OC(=O)C1CC1 YMGUBTXCNDTFJI-UHFFFAOYSA-N 0.000 claims description 3
- ZKQFHRVKCYFVCN-UHFFFAOYSA-N ethoxyethane;hexane Chemical compound CCOCC.CCCCCC ZKQFHRVKCYFVCN-UHFFFAOYSA-N 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- YTKZHDYSHIZVBH-UHFFFAOYSA-N heptane;oxolane;toluene Chemical compound C1CCOC1.CCCCCCC.CC1=CC=CC=C1 YTKZHDYSHIZVBH-UHFFFAOYSA-N 0.000 claims description 3
- PJSYYHUGERWNIH-UHFFFAOYSA-N hexane;oxolane;toluene Chemical compound C1CCOC1.CCCCCC.CC1=CC=CC=C1 PJSYYHUGERWNIH-UHFFFAOYSA-N 0.000 claims description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 3
- 239000011976 maleic acid Substances 0.000 claims description 3
- 239000001630 malic acid Substances 0.000 claims description 3
- 235000011090 malic acid Nutrition 0.000 claims description 3
- 229940098779 methanesulfonic acid Drugs 0.000 claims description 3
- 229960003512 nicotinic acid Drugs 0.000 claims description 3
- 235000001968 nicotinic acid Nutrition 0.000 claims description 3
- 239000011664 nicotinic acid Substances 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- UJJLJRQIPMGXEZ-UHFFFAOYSA-N tetrahydro-2-furoic acid Chemical compound OC(=O)C1CCCO1 UJJLJRQIPMGXEZ-UHFFFAOYSA-N 0.000 claims description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 3
- 229940005605 valeric acid Drugs 0.000 claims description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims description 2
- 159000000021 acetate salts Chemical class 0.000 claims description 2
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 claims description 2
- 239000000010 aprotic solvent Substances 0.000 claims description 2
- 150000004945 aromatic hydrocarbons Chemical class 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 150000008282 halocarbons Chemical class 0.000 claims description 2
- 150000002825 nitriles Chemical class 0.000 claims description 2
- 239000012454 non-polar solvent Substances 0.000 claims description 2
- 239000003208 petroleum Substances 0.000 claims description 2
- 239000002798 polar solvent Substances 0.000 claims description 2
- 239000003586 protic polar solvent Substances 0.000 claims description 2
- 239000011877 solvent mixture Substances 0.000 claims description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 2
- 239000008096 xylene Substances 0.000 claims description 2
- NZNMSOFKMUBTKW-UHFFFAOYSA-N cyclohexanecarboxylic acid Chemical compound OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 claims 4
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 2
- VZFUCHSFHOYXIS-UHFFFAOYSA-N cycloheptane carboxylic acid Natural products OC(=O)C1CCCCCC1 VZFUCHSFHOYXIS-UHFFFAOYSA-N 0.000 claims 2
- MXMUAWYZLLHAEA-UHFFFAOYSA-N 2-(1,3-dioxan-4-yl)acetic acid Chemical compound OC(=O)CC1CCOCO1 MXMUAWYZLLHAEA-UHFFFAOYSA-N 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 239000002994 raw material Substances 0.000 claims 1
- 238000001953 recrystallisation Methods 0.000 abstract description 6
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 abstract description 4
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 abstract description 4
- 229960005370 atorvastatin Drugs 0.000 abstract description 4
- 239000012450 pharmaceutical intermediate Substances 0.000 abstract description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 16
- 239000011541 reaction mixture Substances 0.000 description 12
- 239000013078 crystal Substances 0.000 description 9
- 229910021529 ammonia Inorganic materials 0.000 description 8
- 238000000921 elemental analysis Methods 0.000 description 8
- 238000001914 filtration Methods 0.000 description 8
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 8
- 238000002844 melting Methods 0.000 description 7
- 230000008018 melting Effects 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 238000004440 column chromatography Methods 0.000 description 6
- 238000004508 fractional distillation Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 150000007513 acids Chemical class 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 239000005457 ice water Substances 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 238000001816 cooling Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 238000009835 boiling Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000010779 crude oil Substances 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 229950010765 pivalate Drugs 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- BNGGGQKEDABCQY-UHFFFAOYSA-N 2-[6-(2-aminoethyl)-2,2-dimethyl-1,3-dioxan-4-yl]acetic acid Chemical compound CC1(C)OC(CCN)CC(CC(O)=O)O1 BNGGGQKEDABCQY-UHFFFAOYSA-N 0.000 description 1
- JOLDZLUHNKCCEC-UHFFFAOYSA-N 2-aminoethyl 2-(2,2-dimethyl-1,3-dioxan-4-yl)acetate Chemical group CC1(C)OCCC(CC(=O)OCCN)O1 JOLDZLUHNKCCEC-UHFFFAOYSA-N 0.000 description 1
- ZMROYCGIWPNZNJ-UHFFFAOYSA-N Clobutinol hydrochloride Chemical compound Cl.CN(C)CC(C)C(C)(O)CC1=CC=C(Cl)C=C1 ZMROYCGIWPNZNJ-UHFFFAOYSA-N 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000008107 benzenesulfonic acids Chemical class 0.000 description 1
- LAMJEIALKQRYBY-BTJKTKAUSA-N benzoic acid;(z)-but-2-enedioic acid Chemical compound OC(=O)\C=C/C(O)=O.OC(=O)C1=CC=CC=C1 LAMJEIALKQRYBY-BTJKTKAUSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000020289 caffè mocha Nutrition 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- FPIQZBQZKBKLEI-UHFFFAOYSA-N ethyl 1-[[2-chloroethyl(nitroso)carbamoyl]amino]cyclohexane-1-carboxylate Chemical compound ClCCN(N=O)C(=O)NC1(C(=O)OCC)CCCCC1 FPIQZBQZKBKLEI-UHFFFAOYSA-N 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- GNWXVOQHLPBSSR-UHFFFAOYSA-N oxolane;toluene Chemical compound C1CCOC1.CC1=CC=CC=C1 GNWXVOQHLPBSSR-UHFFFAOYSA-N 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- KUTWWYHQRQQJSM-NDXYWBNTSA-N tert-butyl 2-[(4r,6r)-6-(2-aminoethyl)-2,2-dimethyl-1,3-dioxan-4-yl]acetate;2,2-dimethylpropanoic acid Chemical compound CC(C)(C)C(O)=O.CC(C)(C)OC(=O)C[C@H]1C[C@@H](CCN)OC(C)(C)O1 KUTWWYHQRQQJSM-NDXYWBNTSA-N 0.000 description 1
- HWSHVKNLMBMKSR-UHFFFAOYSA-N tert-butyl 2-[6-(2-aminoethyl)-2,2-dimethyl-1,3-dioxan-4-yl]acetate Chemical compound CC(C)(C)OC(=O)CC1CC(CCN)OC(C)(C)O1 HWSHVKNLMBMKSR-UHFFFAOYSA-N 0.000 description 1
- YNVOMSDITJMNET-UHFFFAOYSA-N thiophene-3-carboxylic acid Chemical compound OC(=O)C=1C=CSC=1 YNVOMSDITJMNET-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
- C07D319/06—1,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings
Abstract
(57)【要約】 本発明は、有機酸によって形成された一般式(I) 【化6】 で表される(4R−シス)−(1,1−ジメチル−エチル)−6−(2−アミノエチル)−2,2−ジメチル−1,3−ジオキサン−4−アセテートの塩に関する。本発明による新規な塩は、安定であり、再結晶によって容易に精製される。本発明の新規な塩は、例えば、一般名称(INN)「atorvastatin」を有する高脂血症剤の製造において使用される貴重な製薬用中間体である。本発明は、さらに、一般式(I)で表される化合物の新規な塩の製法にも関する。 (57) Abstract: The present invention provides a compound represented by the general formula (I): And (4R-cis)-(1,1-dimethyl-ethyl) -6- (2-aminoethyl) -2,2-dimethyl-1,3-dioxane-4-acetate. The novel salts according to the invention are stable and are easily purified by recrystallization. The novel salts of the present invention are valuable pharmaceutical intermediates used, for example, in the manufacture of hyperlipidemic agents having the generic name (INN) "atorvastatin". The present invention further relates to a method for producing a novel salt of the compound represented by the general formula (I).
Description
【0001】 本発明は、新規な製薬用中間体及びその製法に関する。The present invention relates to a novel pharmaceutical intermediate and a method for producing the same.
【0002】 さらに詳述すれば、本発明は、(4R−シス)−(1,1−ジメチル−エチル)−
6−(2−アミノエチル)−2,2−ジメチル−1,3−ジオキサン−4−アセテー
トの有機酸塩に関する。More specifically, the present invention relates to (4R-cis)-(1,1-dimethyl-ethyl)-
The present invention relates to an organic acid salt of 6- (2-aminoethyl) -2,2-dimethyl-1,3-dioxane-4-acetate.
【0003】 一般式(I)The general formula (I)
【化2】 で表される(4R−シス)−(1,1−ジメチル−エチル)−6−(2−アミノエチル
)−2,2−ジメチル−1,3−ジオキサン−4−アセテートは、例えば、一般名
称(INN)「atorvastatin」を有する一般式(II)Embedded image (4R-cis)-(1,1-dimethyl-ethyl) -6- (2-aminoethyl
) -2,2-Dimethyl-1,3-dioxane-4-acetate is, for example, a compound of the general formula (II) having the general name (INN) "atorvastatin"
【化3】 で表される高脂血症剤の製造において使用される貴重な製薬用中間体である。Embedded image Is a valuable pharmaceutical intermediate used in the production of the hyperlipidemic agent represented by
【0004】 一般式(I)で表される化合物の製造に関して、2つの方法が従来技術から知
られている。米国特許第5,155,251号に開示されている方法を、下記の反応スキ
ームAに示す。For the preparation of the compounds of the general formula (I), two methods are known from the prior art. The method disclosed in US Pat. No. 5,155,251 is illustrated in Reaction Scheme A below.
【化4】 Embedded image
【0005】 この特許によれば、125〜135℃/0.05mmHgで分別蒸留を行うことによって、一
般式(I)で表される化合物のアミノエチル誘導体が製造される。生成物の純度
は96%未満である。この方法の欠点は、高真空度における分別蒸留が複雑な精
製法であり、この精製法は、工業的規模では、状況によってのみ実施可能である
点にある。According to this patent, an aminoethyl derivative of the compound represented by the general formula (I) is produced by performing fractional distillation at 125 to 135 ° C./0.05 mmHg. The product purity is less than 96%. The disadvantage of this method is that the fractional distillation at high vacuum is a complicated purification method, which on an industrial scale can only be carried out in certain circumstances.
【0006】 米国特許第5,103,024号及び対応するハンガリー国特許第213,731号に開示され
た方法を反応スキームBに示す。The process disclosed in US Pat. No. 5,103,024 and the corresponding Hungarian patent 213,731 is shown in Reaction Scheme B.
【化5】 Embedded image
【0007】 この特許によれば、一般式(I)で表される化合物は、カラムクロマトグラフ
ィーによって精製される。この方法の欠点は、カラムクロマトグラフィーが多大
の費用を必要とするだけでなく、特に工業的規模での実施が困難である点にある
。得られる生成物の純度は98.2%を越えない。According to this patent, the compounds of the general formula (I) are purified by column chromatography. The disadvantage of this method is that not only is column chromatography expensive, but it is difficult to perform, especially on an industrial scale. The purity of the product obtained does not exceed 98.2%.
【0008】 上記2つの公知の方法の欠点は、分別蒸留又はカラムクロマトグラフィーのい
ずれによっても99%より高い純度を有する生成物を得ることができないことで
ある。A disadvantage of the above two known methods is that neither fractional distillation nor column chromatography can give a product with a purity higher than 99%.
【0009】 本発明の目的は、公知の方法の欠点を解消し、好ましくは、工業的規模でも実
施され、かつ純度99%以上を有する生成物を提供する(4R−シス)−(1,1−
ジメチル−エチル)−6−(2−アミノエチル)−2,2−ジメチル−1,3−ジオ
キサン−4−アセテートの簡単な製法を提供することにある。The object of the present invention is to overcome the disadvantages of the known processes and to provide a product which is preferably carried out on an industrial scale and has a purity of more than 99% (4R-cis)-(1,1) −
It is an object of the present invention to provide a simple method for producing (dimethyl-ethyl) -6- (2-aminoethyl) -2,2-dimethyl-1,3-dioxane-4-acetate.
【0010】 上記目的は、本発明によって達成される。The above object is achieved by the present invention.
【0011】 一般式(I)で表される(4R−シス)−(1,1−ジメチル−エチル)−6−(2
−アミノエチル)−2,2−ジメチル−1,3−ジオキサン−4−アセテートは有
機酸によって塩を形成し、この塩は良好に結晶化され、安定、かつ高純度である
との知見が得られた。塩形である一般式(I)で表される本発明の化合物は極め
て純粋であり、薬局方の要件を満足する純度を有する一般式(II)で表される
「atorvastatin」に有利に変換される。本発明の利点は、従来技術による方法に
おいて使用されていた高真空度で行われる分別蒸留及びカラムクロマトグラフィ
ーを排除できることにある。(4R-cis)-(1,1-dimethyl-ethyl) -6- (2) represented by the general formula (I)
(-Aminoethyl) -2,2-dimethyl-1,3-dioxane-4-acetate forms a salt with an organic acid, and it has been found that this salt is well crystallized, stable, and of high purity. Was done. The compounds of the invention of the general formula (I) in salt form are extremely pure and are advantageously converted to "atorvastatin" of the general formula (II) having a purity satisfying the requirements of the Pharmacopoeia. You. An advantage of the present invention is that it eliminates the fractional distillation and column chromatography performed at high vacuum used in prior art methods.
【0012】 本発明の態様によれば、(4R−シス)−(1,1−ジメチル−エチル)−6−(2
−アミノエチル)−2,2−ジメチル−1,3−ジオキサン−4−アセテートの有
機酸塩が提供される。According to an aspect of the present invention, (4R-cis)-(1,1-dimethyl-ethyl) -6- (2
-Aminoethyl) -2,2-dimethyl-1,3-dioxane-4-acetate is provided.
【0013】 本発明の他の態様によれば、一般式(I)で表される化合物を、有機溶媒中で
、有機酸と反応させることからなる(4R−シス)−(1,1−ジメチル−エチル)
−6−(2−アミノエチル)−2,2−ジメチル−1,3−ジオキサン−4−アセテ
ートの有機酸塩の製法が提供される。According to another aspect of the present invention, the compound represented by the general formula (I) is reacted with an organic acid in an organic solvent, and comprises (4R-cis)-(1,1-dimethyl) -Ethyl)
A process for the preparation of an organic acid salt of -6- (2-aminoethyl) -2,2-dimethyl-1,3-dioxane-4-acetate is provided.
【0014】 本発明は、一般式(I)で表される化合物が、有機酸により、安定な塩を形成
するとの知見に基づくものである。このような知見は、従来技術では、ケタール
は酸の存在下において不安定であることが知られているため、驚くべきことであ
る。一般式(I)で表されるアミン誘導体の2つのヒドロキシル基はケタール環
によって保護される。前記ケタール基が、使用する反応条件下では有機酸に対し
て抵抗性であることは予測されてはいない。本発明の塩が、室温において安定で
あるだけでなく、より高い温度で行われる有機溶媒からの再結晶の間にも安定性
を保持することは、特に驚くべきことである。The present invention is based on the finding that the compound represented by the general formula (I) forms a stable salt with an organic acid. Such a finding is surprising because in the prior art, ketals are known to be unstable in the presence of acids. Two hydroxyl groups of the amine derivative represented by the general formula (I) are protected by a ketal ring. The ketal groups are not expected to be resistant to organic acids under the reaction conditions used. It is particularly surprising that the salts of the present invention are not only stable at room temperature, but also retain stability during recrystallization from organic solvents performed at higher temperatures.
【0015】 本発明の方法によれば、塩形成のために、次の酸:すなわち、脂肪族モノカル
ボン酸、ジカルボン酸又はポリカルボン酸、シクロアルカンカルボン酸、脂肪族
不飽和カルボン酸、芳香族カルボン酸、複素環式カルボン酸又はスルホン酸が使
用される。According to the process of the invention, for the formation of salts, the following acids are used: aliphatic monocarboxylic acids, dicarboxylic acids or polycarboxylic acids, cycloalkanecarboxylic acids, aliphatic unsaturated carboxylic acids, aromatics Carboxylic, heterocyclic carboxylic or sulfonic acids are used.
【0016】 本発明の好適な1実施態様によれば、次の酸が使用される:すなわち、酢酸、
酪酸、吉草酸、イソ吉草酸、ピバル酸、シュウ酸、リンゴ酸、コハク酸、マロン
酸、クエン酸、シクロプロパンカルボン酸、シクロブタンカルボン酸、シクロペ
ンタンカルボン酸、シクロヘキサンカルボン酸、フマル酸、マレイン酸、安息香
酸、m−メチル−安息香酸、4−メトキシ−安息香酸、4−ブロモ−安息香酸、
4−第3級ブチル−安息香酸、ベンゼンスルホン酸、メタンスルホン酸、p−メ
チル−ベンゼンスルホン酸、p−ブロモ−ベンゼンスルホン酸、ニコチン酸、テ
トラヒドロフラン−2−カルボン酸又はチオフェン−3−カルボン酸である。According to one preferred embodiment of the invention, the following acids are used: acetic acid,
Butyric acid, valeric acid, isovaleric acid, pivalic acid, oxalic acid, malic acid, succinic acid, malonic acid, citric acid, cyclopropanecarboxylic acid, cyclobutanecarboxylic acid, cyclopentanecarboxylic acid, cyclohexanecarboxylic acid, fumaric acid, maleic acid Benzoic acid, m-methyl-benzoic acid, 4-methoxy-benzoic acid, 4-bromo-benzoic acid,
4-tert-butyl-benzoic acid, benzenesulfonic acid, methanesulfonic acid, p-methyl-benzenesulfonic acid, p-bromo-benzenesulfonic acid, nicotinic acid, tetrahydrofuran-2-carboxylic acid or thiophen-3-carboxylic acid It is.
【0017】 本発明の特に好適な実施態様によれば、ピバル酸が使用される。According to a particularly preferred embodiment of the present invention, pivalic acid is used.
【0018】 反応は、無極性、極性、非プロトン性又はプロトン性の溶媒中で行われる。反
応媒体として、脂肪族炭化水素、芳香族炭化水素、ハロゲン化炭化水素、エステ
ル、ニトリル、アルコール又はエーテルが使用される。次の溶媒:すなわち、ヘ
キサン、ヘプタン、石油エーテル、トルエン、ベンゼン、キシレン、ジクロロメ
タン、クロロホルム、酢酸エチル、アセトニトリル、メタノール、エタノール、
イソプロパノール、テトラヒドロフラン、ジオキサン又はジエチルエーテルの1
つを使用することが好ましい。The reaction is performed in a non-polar, polar, aprotic or protic solvent. As reaction medium, use is made of aliphatic hydrocarbons, aromatic hydrocarbons, halogenated hydrocarbons, esters, nitriles, alcohols or ethers. The following solvents: hexane, heptane, petroleum ether, toluene, benzene, xylene, dichloromethane, chloroform, ethyl acetate, acetonitrile, methanol, ethanol,
1 of isopropanol, tetrahydrofuran, dioxane or diethyl ether
It is preferred to use one.
【0019】 反応媒体として、溶媒混合物を使用することもできる。ヘプタン−トルエン、
ヘキサン−トルエン、ヘキサン−トルエン−テトラヒドロフラン、ヘプタン−ト
ルエン−テトラヒドロフラン、又はヘキサン−ジエチルエーテルの混合物を使用
することが好ましい。As reaction medium, it is also possible to use solvent mixtures. Heptane-toluene,
It is preferred to use a mixture of hexane-toluene, hexane-toluene-tetrahydrofuran, heptane-toluene-tetrahydrofuran, or hexane-diethyl ether.
【0020】 本発明の特に好ましい実施態様によれば、一般式(I)で表される化合物及び
有機酸を、同種の溶媒を使用して調製した溶液の形で反応させる。According to a particularly preferred embodiment of the present invention, the compound of general formula (I) and the organic acid are reacted in the form of a solution prepared using the same solvents.
【0021】 一般式(I)で表される化合物及び有機酸を、0.5〜5、好ましくは0.5〜
2、特に好ましくは0.5〜1.2のモル比で使用することが好ましい。The compound represented by the general formula (I) and the organic acid are used in an amount of 0.5 to 5, preferably 0.5 to 5.
2, particularly preferably in a molar ratio of 0.5 to 1.2.
【0022】 一般式(I)で表される化合物及び有機酸を、好ましくは室温で混合し、加熱
下又は室温で反応を行う。好ましくは、反応混合物の沸点で操作することができ
る。The compound represented by the general formula (I) and the organic acid are preferably mixed at room temperature, and the reaction is carried out under heating or at room temperature. Preferably, it can be operated at the boiling point of the reaction mixture.
【0023】 簡単な方法によって、反応混合物の反応を終了させることができる。1つの方
法は、好ましくは、反応混合物を冷却させることによって行われ、沈殿した一般
式(I)で表される化合物の塩を濾過又は遠心分離によって単離し、塩を有機溶
媒で洗浄し、乾燥させる。再結晶によって塩を精製できる。The reaction of the reaction mixture can be terminated in a simple manner. One method is preferably carried out by allowing the reaction mixture to cool, isolating the precipitated salt of the compound of formula (I) by filtration or centrifugation, washing the salt with an organic solvent and drying. Let it. The salt can be purified by recrystallization.
【0024】 本発明による製法の好適な1実施態様によれば、原料物質として、一般式(I
)で表される粗製の化合物を使用する。この場合、一般式(I)で表される化合
物の高価かつ複雑な精製が排除される。According to one preferred embodiment of the process according to the invention, the starting material is a compound of general formula (I)
) Is used. In this case, expensive and complicated purification of the compound represented by the general formula (I) is excluded.
【0025】 本発明の利点は、下記のように要約される。The advantages of the present invention are summarized as follows.
【0026】 本発明によれば、一般式(I)で表される化合物は、公知の方法において使用
されているような、高真空度において行われる分別蒸留及びカラムクロマトグラ
フィーよりも明らかに容易に行われる再結晶によって精製される。According to the invention, the compounds of the general formula (I) are clearly more readily available than fractional distillation and column chromatography carried out at high vacuum, as used in known methods. Purified by recrystallization performed.
【0027】 本発明は、従来の方法よりも高い純度を有する生成物を提供できる。1回の再
結晶工程の後では、生成物の純度は>99%(ガスクロマトグラフィーによる)
であり、再結晶を2回行った後では、純度は>99.95%となる。公知の方法で得
られる生成物の純度は98%未満である。The present invention can provide a product having a higher purity than the conventional method. After one recrystallization step, the purity of the product is> 99% (by gas chromatography)
After two recrystallizations, the purity is> 99.95%. The purity of the products obtained in known manner is less than 98%.
【0028】 本発明の製法は、工業的規模においても容易に実施される。スケールアップは
何ら問題を生じない。一方、高真空度において行われる分別蒸留及びカラムクロ
マトグラフィーは、多大の費用を必要とするだけでなく、工業的規模での実施が
困難である。The process of the present invention is easily carried out on an industrial scale. Scale-up does not cause any problems. On the other hand, fractional distillation and column chromatography performed at a high vacuum not only require a great deal of expense, but are also difficult to implement on an industrial scale.
【0029】 一般式(I)で表される化合物は安定であり、有機酸によって形成された塩の
形で、分解することなく長期間保存される。The compounds of the general formula (I) are stable and can be stored for a long time without decomposition in the form of salts formed with organic acids.
【0030】 本発明による一般式(I)で表される化合物の高純度の塩から、薬局方の要件
を満足する「atorvastatin」が調製される。From the highly pure salts of the compounds of the general formula (I) according to the invention, "atorvastatin" which meets the requirements of the Pharmacopoeia is prepared.
【0031】 本発明の更なる詳細は、下記の実施例において見られるであろう。ただし、本
発明の保護の範囲は実施例に限定されない。Further details of the present invention will be found in the examples below. However, the scope of protection of the present invention is not limited to the embodiments.
【0032】[0032]
【実施例1】 (4R−シス)−(1,1−ジメチル−エチル)−6−(2−アミノエチル)−2,2 −ジメチル−1,3−ジオキサン−4−アセテートのピバル酸塩 粗製の油状(4R−シス)−(1,1−ジメチル−エチル)−6−(2−アミノエチ
ル)−2,2−ジメチル−1,3−ジオキサン−4−アセテート55gを、ヘプタ
ン−トルエンの4:1混合物500mlに溶解させた。また、ピバル酸20.6g(201ミ
リモル)を、ヘプタン−トルエンの4:1混合物190mlに溶解させた。2つの溶
液を混合し、反応混合物を1時間還流させた。熱い溶液を濾過し、混合物を、撹
拌下、氷水によって冷却した。沈殿した結晶を濾取し、ヘプタン−トルエンの冷
たい混合物によって洗浄し、乾燥させた。このようにして、所望の化合物64.9g
(172ミリモル)が得られた。 収率:86% 融点:131℃ 元素分析: C% H% N% 理論値 60.77 9.93 3.73 測定値 60.77 9.88 3.81 TLC(プロパノール:アンモニア=7:3):Rf=0.63 IR(KBr):2949,1725,1520,1173 HNMR(DMSO,i400):4.17(m,1H),3.98(m,1H),2.66(m,2H),2.36(d
d,J1=4.9Hz,J2=15.0Hz,1H),2.22(dd,J1=8.1Hz,J2=15.0Hz,1H),1
.54(m,3H),1.39(s,12H),1.24(s,3H),1.05(s,9H),1.03(〜t,J
=12.0Hz,1H) CNMR:180.87,169.77,98.22,79.85,66.50,66.12,42.34,38.26,37.05,3
6.44,35.97,30.11,28.03,27.92,19.88 MS:274(3),202(57),200(47),173(44),158(50),57(100),41(48),30(96
) GC含量:>99% ジアステレオマー汚染:<0.7%Example 1 Crude pivalate salt of (4R-cis)-(1,1-dimethyl-ethyl) -6- (2-aminoethyl) -2,2 -dimethyl-1,3-dioxane-4-acetate 55 g of oily (4R-cis)-(1,1-dimethyl-ethyl) -6- (2-aminoethyl) -2,2-dimethyl-1,3-dioxane-4-acetate in 4 parts of heptane-toluene : 1 mixture was dissolved in 500 ml. Also, 20.6 g (201 mmol) of pivalic acid was dissolved in 190 ml of a 4: 1 mixture of heptane-toluene. The two solutions were mixed and the reaction mixture was refluxed for 1 hour. The hot solution was filtered and the mixture was cooled with ice water under stirring. The precipitated crystals were collected by filtration, washed with a cold mixture of heptane-toluene and dried. Thus, 64.9 g of the desired compound
(172 mmol) were obtained. Yield: 86% Melting point: 131 ° C Elemental analysis: C% H% N% Theoretical 60.77 9.93 3.73 Found 60.77 9.88 3.81 TLC (propanol: ammonia = 7: 3): R f = 0.63 IR (KBr): 2949, 1725, 1520, 1173 H NMR (DMSO, i400): 4.17 (m, 1H), 3.98 (m, 1H), 2.66 (m, 2H), 2.36 (d
d, J1 = 4.9 Hz, J2 = 15.0 Hz, 1H), 2.22 (dd, J1 = 8.1 Hz, J2 = 15.0 Hz, 1H), 1
.54 (m, 3H), 1.39 (s, 12H), 1.24 (s, 3H), 1.05 (s, 9H), 1.03 (~ t, J
= 12.0Hz, 1H) CNMR: 180.87, 169.77, 98.22, 79.85, 66.50, 66.12, 42.34, 38.26, 37.05, 3
6.44, 35.97, 30.11, 28.03, 27.92, 19.88 MS: 274 (3), 202 (57), 200 (47), 173 (44), 158 (50), 57 (100), 41 (48), 30 ( 96
) GC content:> 99% Diastereomeric contamination: <0.7%
【0033】[0033]
【実施例2】 (4R−シス)−(1,1−ジメチル−エチル)−6−(2−アミノエチル)−2,2 −ジメチル−1,3−ジオキサン−4−アセテートのピバル酸塩 1回再結晶した(4R−シス)−(1,1−ジメチル−エチル)−6−(2−アミノ
エチル)−2,2−ジメチル−1,3−ジオキサン−4−アセテートのピバル酸塩2
3.3gを、ヘキサン−トルエンの4:1混合物220mlに溶解させた。溶液を加熱、
還流させ、熱い溶液を濾取し、混合物を、撹拌下、氷水によって冷却した。沈殿
した結晶を濾過し、冷たいジエチルエーテルで洗浄し、乾燥させた。このように
して、所望の生成物20.7gが得られた。 収率:89% 融点:132〜133℃ GC含量:>99.95% 総不純物:<0.05%Example 2 Pivalate of (4R-cis)-(1,1-dimethyl-ethyl) -6- (2-aminoethyl) -2,2 -dimethyl-1,3-dioxane-4-acetate 1 (4R-cis)-(1,1-dimethyl-ethyl) -6- (2-aminoethyl) -2,2-dimethyl-1,3-dioxane-4-acetate pivalate 2
3.3 g were dissolved in 220 ml of a 4: 1 mixture of hexane-toluene. Heating the solution,
At reflux, the hot solution was filtered off and the mixture was cooled with ice water under stirring. The precipitated crystals were filtered, washed with cold diethyl ether and dried. In this way, 20.7 g of the desired product are obtained. Yield: 89% Melting point: 132-133 ° C GC content:> 99.95% Total impurities: <0.05%
【0034】[0034]
【実施例3】 (4R−シス)−(1,1−ジメチル−エチル)−6−(2−アミノエチル)−2,2 −ジメチル−1,3−ジオキサン−4−アセテートのピバル酸塩 粗製の油状(4R−シス)−(1,1−ジメチル−エチル)−6−(2−アミノエチ
ル)−2,2−ジメチル−1,3−ジオキサン−4−アセテート21gを、ヘキサ
ン−トルエン−テトラヒドロフランの2:2:1混合物116mlに溶解させた。ま
た、ピバル酸7.6g(74ミリモル)を、ヘキサン−トルエンの1:1混合物
53ml中に溶解させた。2つの溶液を混合し、反応混合物を、還流しながら、加
熱沸騰させた。熱い溶液を濾取し、混合物を、撹拌下、氷水によって冷却した。
沈殿した結晶を濾過し、冷たいジエチルエーテルで洗浄し、乾燥させた。このよ
うにして、所望の生成物21.1gが得られた。 収率:73% 融点:131℃Example 3 Crude pivalate of (4R-cis)-(1,1-dimethyl-ethyl) -6- (2-aminoethyl) -2,2 -dimethyl-1,3-dioxane-4-acetate 21 g of oil (4R-cis)-(1,1-dimethyl-ethyl) -6- (2-aminoethyl) -2,2-dimethyl-1,3-dioxane-4-acetate in hexane-toluene-tetrahydrofuran Was dissolved in 116 ml of a 2: 2: 1 mixture. Also, 7.6 g (74 mmol) of pivalic acid were dissolved in 53 ml of a 1: 1 mixture of hexane-toluene. The two solutions were mixed and the reaction mixture was heated to the boil while refluxing. The hot solution was filtered off and the mixture was cooled with ice water under stirring.
The precipitated crystals were filtered, washed with cold diethyl ether and dried. In this way, 21.1 g of the desired product are obtained. Yield: 73% Melting point: 131 ° C
【0035】[0035]
【実施例4】 (4R−シス)−(1,1−ジメチル−エチル)−6−(2−アミノエチル)−2,2 −ジメチル−1,3−ジオキサン−4−アセテートのピバル酸塩 粗製の油状(4R−シス)−(1,1−ジメチル−エチル)−6−(2−アミノエチ
ル)−2,2−ジメチル−1,3−ジオキサン−4−アセテート24g(87.8ミリ
モル)を、ヘプタン−トルエン−テトラヒドロフランの4:1:1混合物200ml
に溶解させた。また、ピバル酸9.0g(88ミリモル)を、ヘプタン−トルエ
ン−テトラヒドロフランの4:1:1混合物100mlに溶解させた。2つの溶液を
混合し、反応混合物を、還流下、加熱沸騰させた。熱い溶液を濾過し、混合物を
、撹拌下、氷水によって冷却した。沈殿した結晶を濾取し、冷たいジエチルエー
テルで洗浄し、乾燥させた。このようにして、所望の生成物29.0gが得られた。
収率:88% 融点:131℃Example 4 Crude pivalate salt of (4R-cis)-(1,1-dimethyl-ethyl) -6- (2-aminoethyl) -2,2 -dimethyl-1,3-dioxane-4-acetate Oil (4R-cis)-(1,1-dimethyl-ethyl) -6- (2-aminoethyl) -2,2-dimethyl-1,3-dioxane-4-acetate (24 g, 87.8 mmol) in heptane 200 ml of a 4: 1: 1 mixture of toluene-tetrahydrofuran
Was dissolved. In addition, 9.0 g (88 mmol) of pivalic acid was dissolved in 100 ml of a 4: 1: 1 mixture of heptane-toluene-tetrahydrofuran. The two solutions were mixed and the reaction mixture was heated to boiling under reflux. The hot solution was filtered and the mixture was cooled with ice water under stirring. The precipitated crystals were collected by filtration, washed with cold diethyl ether and dried. In this way, 29.0 g of the desired product are obtained.
Yield: 88% Melting point: 131 ° C
【0036】[0036]
【実施例5】 (4R−シス)−(1,1−ジメチル−エチル)−6−(2−アミノエチル)−2,2 −ジメチル−1,3−ジオキサン−4−アセテートの安息香酸塩 粗製の(4R−シス)−(1,1−ジメチル−エチル)−6−(2−アミノエチル)
−2,2−ジメチル−1,3−ジオキサン−4−アセテート0.6g(2.19ミリモ
ル)を、酢酸エチル4mlに溶解させた。また、安息香酸0.26gを、ヘキサン−ジ
エチルエーテルの1:1混合物8mlに溶解させた。2つの溶液を混合し、室温で
1時間攪拌した。反応混合物を真空中で蒸発させた。残渣を、ヘキサン−トルエ
ンの4:1混合物5mlから再結晶させた。冷却後、沈殿した結晶を濾取し、冷た
いヘキサンで洗浄し、乾燥させた。このようにして、所望の化合物0.71gが得ら
れた。 収率:82% 融点:113〜114℃ 化学式:C21H33NO6 分子量:395.500 元素分析: C% H% N% 理論値 63.78 8.41 3.54 測定値 63.74 8.38 3.55 TLC(プロパノール:アンモニア=7:3):Rf=0.63 IR(KBr):2979,1722,1519,1370 HNMR(CDCl3,g200):8.39(b,3H),7.98(〜d,J=7.0Hz,2H),7.39(m,
3H),4.13(m,1H),3.79(m,1H),2.97(m,2H),2.23(m,2H),1.70(
m,2H),1.43(s,9H),1.32(s,3H),1.27(s,3H),1.00(m,2H)Example 5 Crude benzoate of (4R-cis)-(1,1-dimethyl-ethyl) -6- (2-aminoethyl) -2,2 -dimethyl-1,3-dioxane-4-acetate (4R-cis)-(1,1-dimethyl-ethyl) -6- (2-aminoethyl)
0.6 g (2.19 mmol) of -2,2-dimethyl-1,3-dioxane-4-acetate was dissolved in 4 ml of ethyl acetate. Also, 0.26 g of benzoic acid was dissolved in 8 ml of a 1: 1 mixture of hexane-diethyl ether. The two solutions were mixed and stirred at room temperature for 1 hour. The reaction mixture was evaporated in vacuum. The residue was recrystallized from 5 ml of a 4: 1 mixture of hexane-toluene. After cooling, the precipitated crystals were collected by filtration, washed with cold hexane and dried. In this way 0.71 g of the desired compound is obtained. Yield: 82% Melting point: 113-114 ° C Chemical formula: C 21 H 33 NO 6 Molecular weight: 395.500 Elemental analysis: C% H% N% Theoretical 63.78 8.41 3.54 Found 63.74 8.38 3.55 TLC (propanol: ammonia = 7: 3 ): R f = 0.63 IR (KBr): 2979, 1722, 1519, 1370 H NMR (CDCl 3 , g200): 8.39 (b, 3H), 7.98 (-d, J = 7.0 Hz, 2H), 7.39 (m,
3H), 4.13 (m, 1H), 3.79 (m, 1H), 2.97 (m, 2H), 2.23 (m, 2H), 1.70 (
m, 2H), 1.43 (s, 9H), 1.32 (s, 3H), 1.27 (s, 3H), 1.00 (m, 2H)
【0037】[0037]
【実施例6】 (4R−シス)−(1,1−ジメチル−エチル)−6−(2−アミノエチル)−2,2 −ジメチル−1,3−ジオキサン−4−アセテートのマレイン酸塩 粗製の油状(4R−シス)−(1,1−ジメチル−エチル)−6−(2−アミノエチ
ル)−2,2−ジメチル−1,3−ジオキサン−4−アセテート0.6g(2.19ミリ
モル)を、ジエチルエーテル6mlに溶解させた。また、マレイン酸0.25g(2.19
ミリモル)を、ジエチルエーテル4mlに溶解させた。2つの溶液を混合し、室温
で攪拌した。冷却後、沈殿した結晶を濾取し、冷たいヘキサンで洗浄し、乾燥さ
せた。このようにして、所望の化合物0.80gが得られた。 収率:93% 融点:87〜89℃ 化学式:C18H31NO8 分子量:389.450 元素分析: C% H% N% 理論値 55.51 8.02 3.60 測定値 54.70 8.12 3.52 TLC(プロパノール:アンモニア=7:3):Rf=0.63 IR(KBr):3430,2980,1722 HNMR(CDCl3,i400):7.97(b,3H),6.25(s,2H),4.28(m,1H),4.10(
m,1H),3.21(m,2H),2.40(m,1H),2.31(m,1H),1.89(m,2H),1.5
7(m,1H),1.46(s,3H),1.44(s,9H),1.35(s,3H),1.27(m,1H)Example 6 Crude maleate salt of (4R-cis)-(1,1-dimethyl-ethyl) -6- (2-aminoethyl) -2,2 -dimethyl-1,3-dioxane-4-acetate Of oil (4R-cis)-(1,1-dimethyl-ethyl) -6- (2-aminoethyl) -2,2-dimethyl-1,3-dioxane-4-acetate (0.6 g, 2.19 mmol). Was dissolved in 6 ml of diethyl ether. In addition, maleic acid 0.25 g (2.19
Mmol) was dissolved in 4 ml of diethyl ether. The two solutions were mixed and stirred at room temperature. After cooling, the precipitated crystals were collected by filtration, washed with cold hexane and dried. In this way 0.80 g of the desired compound is obtained. Yield: 93% mp: 87-89 ° C. Chemical formula: C 18 H 31 NO 8 molecular weight: 389.450 Elemental analysis: C% H% N% theoretical value 55.51 8.02 3.60 measurements 54.70 8.12 3.52 TLC (propanol: ammonia = 7: 3 ): R f = 0.63 IR (KBr): 3430, 2980, 1722 HNMR (CDCl 3 , i400): 7.97 (b, 3H), 6.25 (s, 2H), 4.28 (m, 1H), 4.10 (
m, 1H), 3.21 (m, 2H), 2.40 (m, 1H), 2.31 (m, 1H), 1.89 (m, 2H), 1.5
7 (m, 1H), 1.46 (s, 3H), 1.44 (s, 9H), 1.35 (s, 3H), 1.27 (m, 1H)
【0038】[0038]
【実施例7】 (4R−シス)−(1,1−ジメチル−エチル)−6−(2−アミノエチル)−2,2 −ジメチル−1,3−ジオキサン−4−アセテートのフマル酸塩 粗製の油状(4R−シス)−(1,1−ジメチル−エチル)−6−(2−アミノエチ
ル)−2,2−ジメチル−1,3−ジオキサン−4−アセテート0.6g(2.19ミリ
モル)を、無水エタノール4mlに溶解させた。また、フマル酸0.25g(2.19ミリ
モル)を、無水エタノール10mlに溶解させた。2つの溶液を混合し、室温で攪
拌した。反応混合物を蒸発させ、残渣をヘキサン中に懸濁させた。冷却後、沈殿
した結晶を濾取し、2−プロパノールから再結晶させた。このようにして、所望
の化合物0.75gが得られた。 収率:85% 融点:145〜148℃ 化学式:C18H31NO8 分子量:389.450 元素分析: C% H% N% 理論値 55.51 8.02 3.60 測定値 55.31 8.04 3.55 TLC(プロパノール:アンモニア=7:3):Rf=0.63 IR(KBr):3430,2988,1736,1157 HNMR(DMSO,g200):8.52(b,3H),6.44(s,2H),4.17(m,1H),3.98(m
,1H),2.80(m,2H),2.36(m,1H),2.19(m,1H),1.68(m,2H),1.58
(m,1H),1.38(m,12H),1.24(m,3H),1.09(m,1H)Example 7 Crude fumarate of (4R-cis)-(1,1-dimethyl-ethyl) -6- (2-aminoethyl) -2,2 -dimethyl-1,3-dioxane-4-acetate Of oil (4R-cis)-(1,1-dimethyl-ethyl) -6- (2-aminoethyl) -2,2-dimethyl-1,3-dioxane-4-acetate (0.6 g, 2.19 mmol). Was dissolved in 4 ml of absolute ethanol. Also, 0.25 g (2.19 mmol) of fumaric acid was dissolved in 10 ml of anhydrous ethanol. The two solutions were mixed and stirred at room temperature. The reaction mixture was evaporated and the residue was suspended in hexane. After cooling, the precipitated crystals were collected by filtration and recrystallized from 2-propanol. In this way 0.75 g of the desired compound is obtained. Yield: 85% Melting point: 145-148 ° C Chemical formula: C 18 H 31 NO 8 Molecular weight: 389.450 Elemental analysis: C% H% N% Theoretical 55.51 8.02 3.60 Found 55.31 8.04 3.55 TLC (propanol: ammonia = 7: 3 ): R f = 0.63 IR (KBr): 3430, 2988, 1736, 1157 H NMR (DMSO, g200): 8.52 (b, 3H), 6.44 (s, 2H), 4.17 (m, 1H), 3.98 (m
, 1H), 2.80 (m, 2H), 2.36 (m, 1H), 2.19 (m, 1H), 1.68 (m, 2H), 1.58
(M, 1H), 1.38 (m, 12H), 1.24 (m, 3H), 1.09 (m, 1H)
【0039】[0039]
【実施例8】 (4R−シス)−(1,1−ジメチル−エチル)−6−(2−アミノエチル)−2,2 −ジメチル−1,3−ジオキサン−4−アセテートのm−メチル−安息香酸塩 粗製の油状(4R−シス)−(1,1−ジメチル−エチル)−6−(2−アミノエチ
ル)−2,2−ジメチル−1,3−ジオキサン−4−アセテート0.6g(2.19ミリ
モル)を、ジエチルエーテル6mlに溶解させた。また、メタ−メチル−安息香酸
0.3g(2.19ミリモル)を、ジエチルエーテル3mlに溶解させた。2つの溶液
を混合し、室温で攪拌した。反応混合物を蒸発させ、残渣を、ヘキサン−トルエ
ンの5:1混合物から再結晶させた。このようにして、所望の化合物0.84gが得
られた。 収率:92% 融点:95〜96℃ 化学式:C22H35NO6 分子量:409.527 元素分析: C% H% N% 理論値 64.52 8.61 3.42 測定値 64.23 8.64 3.45 TLC(プロパノール:アンモニア=7:3):Rf=0.63 IR(KBr):2977,2200,1722,1367 HNMR(CDCl3,i400):8.86(b,3H),7.79(m,1H),7.77(m,1H),7.24(
m,2H),4.13(m,1H),3.79(m,1H),3.02(m,1H),2.93(m,1H),2.3
7(s,3H),2.31(m,1H),2.18(m,1H),1.71(m,2H),1.50(m,1H),
1.43(s,9H),1.33(s,3H),1.26(s,3H),1.00(m,1H)Example 8 m-methyl- (4R-cis)-(1,1-dimethyl-ethyl) -6- (2-aminoethyl) -2,2 -dimethyl-1,3-dioxane-4-acetate 0.6 g of crude oil of benzoate (4R-cis)-(1,1-dimethyl-ethyl) -6- (2-aminoethyl) -2,2-dimethyl-1,3-dioxane-4-acetate ( 2.19 mmol) was dissolved in 6 ml of diethyl ether. Also, 0.3 g (2.19 mmol) of meta-methyl-benzoic acid was dissolved in 3 ml of diethyl ether. The two solutions were mixed and stirred at room temperature. The reaction mixture was evaporated and the residue was recrystallized from a 5: 1 mixture of hexane-toluene. In this way 0.84 g of the desired compound is obtained. Yield: 92% mp: 95-96 ° C. Chemical formula: C 22 H 35 NO 6 Molecular weight: 409.527 Elemental analysis: C% H% N% theoretical value 64.52 8.61 3.42 measurements 64.23 8.64 3.45 TLC (propanol: ammonia = 7: 3 ): R f = 0.63 IR (KBr): 2977, 2200, 1722, 1367 H NMR (CDCl 3 , i400): 8.86 (b, 3H), 7.79 (m, 1H), 7.77 (m, 1H), 7.24 (
m, 2H), 4.13 (m, 1H), 3.79 (m, 1H), 3.02 (m, 1H), 2.93 (m, 1H), 2.3
7 (s, 3H), 2.31 (m, 1H), 2.18 (m, 1H), 1.71 (m, 2H), 1.50 (m, 1H),
1.43 (s, 9H), 1.33 (s, 3H), 1.26 (s, 3H), 1.00 (m, 1H)
【0040】[0040]
【実施例9】 (4R−シス)−(1,1−ジメチル−エチル)−6−(2−アミノエチル)−2,2 −ジメチル−1,3−ジオキサン−4−アセテートのベンゼンスルホン酸塩 粗製の油状(4R−シス)−(1,1−ジメチル−エチル)−6−(2−アミノエチ
ル)−2,2−ジメチル−1,3−ジオキサン−4−アセテート0.6g(2.19ミリ
モル)を、ヘキサン−トルエンの4:1混合物5mlに溶解させた。また、ベンゼ
ンスルホン酸0.34g(2.19ミリモル)を、トルエン5mlに溶解させた。2つの溶
液を混合した。反応混合物を室温で攪拌し、真空中で蒸発させた。残渣をヘキサ
ン−トルエンの5:1混合物から再結晶させた。このようにして、所望の化合物
0.76gが得られた。 収率:80% 融点:96〜98℃ 化学式:C20H33NO7S 分子量:431.553 元素分析: C% H% S% N% 理論値 55.66 7.71 7.43 3.25 測定値 54.79 7.73 7.32 3.28 TLC(プロパノール:アンモニア=7:3):Rf=0.63 IR(KBr):3430,2976,1737,1719,1165 HNMR(CDCl3,i400):7.90(m,1H),7.63(m,2H),7.40(m,2H),4.13(
m,1H),3.82(m,1H),2.98(m,2H),2.33(m,1H),3.21(m,1H),1.6
8(m,2H),1.50(m,1H),1.44(s,9H),1.33(s,3H),1.27(s,3H),
1.03(m,1H)Example 9 Benzenesulfonic acid salt of (4R-cis)-(1,1-dimethyl-ethyl) -6- (2-aminoethyl) -2,2 -dimethyl-1,3-dioxane-4-acetate 0.6 g (2.19 mmol) of crude oily (4R-cis)-(1,1-dimethyl-ethyl) -6- (2-aminoethyl) -2,2-dimethyl-1,3-dioxane-4-acetate Was dissolved in 5 ml of a 4: 1 mixture of hexane-toluene. Also, 0.34 g (2.19 mmol) of benzenesulfonic acid was dissolved in 5 ml of toluene. The two solutions were mixed. The reaction mixture was stirred at room temperature and evaporated in vacuo. The residue was recrystallized from a 5: 1 mixture of hexane-toluene. Thus, the desired compound
0.76 g was obtained. Yield: 80% mp: 96 to 98 ° C. Formula: C 20 H 33 NO 7 S Molecular weight: 431.553 Elemental analysis: C% H% S% N % theoretical value 55.66 7.71 7.43 3.25 measurements 54.79 7.73 7.32 3.28 TLC (propanol: ammonia = 7: 3): R f = 0.63 IR (KBr): 3430,2976,1737,1719,1165 HNMR (CDCl 3, i400): 7.90 (m, 1H), 7.63 (m, 2H), 7.40 (m , 2H), 4.13 (
m, 1H), 3.82 (m, 1H), 2.98 (m, 2H), 2.33 (m, 1H), 3.21 (m, 1H), 1.6
8 (m, 2H), 1.50 (m, 1H), 1.44 (s, 9H), 1.33 (s, 3H), 1.27 (s, 3H),
1.03 (m, 1H)
【0041】[0041]
【実施例10】 (4R−シス)−(1,1−ジメチル−エチル)−6−(2−アミノエチル)−2,2 −ジメチル−1,3−ジオキサン−4−アセテートの酢酸塩 粗製の油状(4R−シス)−(1,1−ジメチル−エチル)−6−(2−アミノエチ
ル)−2,2−ジメチル−1,3−ジオキサン−4−アセテート0.6g(2.19ミリ
モル)を、ジエチルエーテル6mlに溶解させた。また、酢酸0.131g(2.19ミリ
モル)を、ジエチルエーテル5mlに溶解させた。2つの溶液を混合した。反応混
合物を室温で攪拌した。結晶を濾取し、ヘキサンで洗浄し、真空中、室温で乾燥
させた。このようにして、所望の化合物0.56gが得られた。 収率:76% 融点:76〜77℃ 化学式:C16H31NO6 分子量:333.429 元素分析: C% H% N% 理論値 57.64 9.37 4.20 測定値 57.80 9.40 4.09 TLC(プロパノール:アンモニア=7:3):Rf=0.63 IR(KBr):3430,2986,1731,1157 HNMR(CDCl3,i400):8.18(b,3H),4.26(m,1H),3.97(m,1H),2.93(
m,2H),2.43(m,1H),2.29(m,1H),1.96(s,3H),1.80(m,2H),1.5
6(m,1H),1.44(s,9H),1.44(s,3H),1.34(s,3H),1.22(m,1H)Example 10 Preparation of crude acetate salt of (4R-cis)-(1,1-dimethyl-ethyl) -6- (2-aminoethyl) -2,2 -dimethyl-1,3-dioxane-4-acetate 0.6 g (2.19 mmol) of oily (4R-cis)-(1,1-dimethyl-ethyl) -6- (2-aminoethyl) -2,2-dimethyl-1,3-dioxane-4-acetate was obtained. It was dissolved in 6 ml of diethyl ether. In addition, 0.131 g (2.19 mmol) of acetic acid was dissolved in 5 ml of diethyl ether. The two solutions were mixed. The reaction mixture was stirred at room temperature. The crystals were collected by filtration, washed with hexane and dried in vacuo at room temperature. In this way 0.56 g of the desired compound is obtained. Yield: 76% Melting point: 76-77 ° C Chemical formula: C 16 H 31 NO 6 Molecular weight: 333.429 Elemental analysis: C% H% N% Theoretical 57.64 9.37 4.20 Measurement 57.80 9.40 4.09 TLC (propanol: ammonia = 7: 3 ): R f = 0.63 IR (KBr): 3430, 2986, 1731, 1157 H NMR (CDCl 3 , i400): 8.18 (b, 3H), 4.26 (m, 1H), 3.97 (m, 1H), 2.93 (
m, 2H), 2.43 (m, 1H), 2.29 (m, 1H), 1.96 (s, 3H), 1.80 (m, 2H), 1.5
6 (m, 1H), 1.44 (s, 9H), 1.44 (s, 3H), 1.34 (s, 3H), 1.22 (m, 1H)
【0042】[0042]
【実施例11】 ビス−(4R−シス)−(1,1−ジメチル−エチル)−6−(2−アミノエチル)
−2,2−ジメチル−1,3−ジオキサン−4−アセテートシュウ酸塩 粗製の油状(4R−シス)−(1,1−ジメチル−エチル)−6−(2−アミノエチ
ル)−2,2−ジメチル−1,3−ジオキサン−4−アセテート0.6g(2.19ミリ
モル)を、ジエチルエーテル6mlに溶解させた。また、シュウ酸0.19g(2.19ミ
リモル)を、ジエチルエーテル3mlに溶解させた。2つの溶液を混合した。反応
混合物を室温で攪拌した。沈殿した結晶を濾取し、冷たいヘキサンで洗浄し、真
空中、室温で乾燥させた。このようにして、所望の化合物0.56gが得られた。 収率:80% 融点:76〜77℃ 化学式:C30H56N2O12 分子量:636.725 元素分析: C% H% N% 理論値 56.59 8.86 4.40 測定値 56.21 8.38 4.36 TLC(プロパノール:アンモニア=7:3):Rf=0.63 IR(KBr):3430,2982,1739,1161 HNMR(CDCl3,i400):8.60(b,3H),4.24(m,1H),3.99(m,1H),3.00(
m,2H),2.32(m,2H),1.90(m,2H),1.54(m,1H),1.44(s,9H),1.4
1(s,3H),1.32(s,3H),1.21(m,1H)Example 11 Bis- (4R-cis)-(1,1-dimethyl-ethyl) -6- (2-aminoethyl)
-2,2-dimethyl-1,3-dioxane-4-acetate oxalate crude oil (4R-cis)-(1,1-dimethyl-ethyl) -6- (2-aminoethyl) -2,2 0.6 g (2.19 mmol) of -dimethyl-1,3-dioxane-4-acetate were dissolved in 6 ml of diethyl ether. Also, 0.19 g (2.19 mmol) of oxalic acid was dissolved in 3 ml of diethyl ether. The two solutions were mixed. The reaction mixture was stirred at room temperature. The precipitated crystals were collected by filtration, washed with cold hexane and dried in vacuo at room temperature. In this way 0.56 g of the desired compound is obtained. Yield: 80% mp: 76-77 ° C. Chemical formula: C 30 H 56 N 2 O 12 Molecular weight: 636.725 Elemental analysis: C% H% N% theoretical value 56.59 8.86 4.40 measurements 56.21 8.38 4.36 TLC (propanol: ammonia = 7 : 3): R f = 0.63 IR (KBr): 3430,2982,1739,1161 HNMR (CDCl 3, i400): 8.60 (b, 3H), 4.24 (m, 1H), 3.99 (m, 1H), 3.00 (
m, 2H), 2.32 (m, 2H), 1.90 (m, 2H), 1.54 (m, 1H), 1.44 (s, 9H), 1.4
1 (s, 3H), 1.32 (s, 3H), 1.21 (m, 1H)
───────────────────────────────────────────────────── フロントページの続き (81)指定国 EP(AT,BE,CH,CY, DE,DK,ES,FI,FR,GB,GR,IE,I T,LU,MC,NL,PT,SE),OA(BF,BJ ,CF,CG,CI,CM,GA,GN,GW,ML, MR,NE,SN,TD,TG),AP(GH,GM,K E,LS,MW,SD,SL,SZ,TZ,UG,ZW ),EA(AM,AZ,BY,KG,KZ,MD,RU, TJ,TM),AE,AG,AL,AM,AT,AU, AZ,BA,BB,BG,BR,BY,CA,CH,C N,CR,CU,CZ,DE,DK,DM,DZ,EE ,ES,FI,GB,GD,GE,GH,GM,HR, ID,IL,IN,IS,JP,KE,KG,KP,K R,KZ,LC,LK,LR,LS,LT,LU,LV ,MA,MD,MG,MK,MN,MW,MX,NO, NZ,PL,PT,RO,RU,SD,SE,SG,S I,SK,SL,TJ,TM,TR,TT,TZ,UA ,UG,US,UZ,VN,YU,ZA,ZW (72)発明者 ヨーゼフ バルコーツィ ハンガリー国 ハー−1016 ブダペスト シロム ウッツァ 4−6ベー (72)発明者 ジューラ シミグ ハンガリー国 ハー−1126 ブダペスト ホロースイ エシュ ウッツァ 25 (72)発明者 ラースロー バラージュ ハンガリー国 ハー−1088 ブダペスト バロシュ ウッツァ 38 (72)発明者 イムレ ドマン ハンガリー国 ハー−1035 ブダペスト モハーチュ ウッツァ 18ベー (72)発明者 ゾルターン ラートカイ ハンガリー国 ハー−1101 ブダペスト モノリ ウッツァ 19 (72)発明者 ペーター セレシュ ハンガリー国 ハー−1153 ブダペスト レッダ バルネン ウッツァ 6 (72)発明者 フェレンツ バルタ ハンガリー国 ハー−4440 ティサヴァシ ュヴァーリ カバイ ウッツァ 3−5 /5 (72)発明者 ジョルジー ヴェレツケイネー ドナート ハンガリー国 ハー−1036 ブダペスト ラヨーシュ ウッツァ 49ベー (72)発明者 カールマーン ナジ ハンガリー国 ハー−1025 ブダペスト ツリシュタ ウッツァ 2ア Fターム(参考) 4C022 GA07 ──────────────────────────────────────────────────続 き Continuation of front page (81) Designated country EP (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE ), OA (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG), AP (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), EA (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR , ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW (72) Inventor Josef Barcoczi Hungary Hah 1016 Budapest Silom Uzza 4-6b (72) Inventor Jura Simig Hungary Hah-1126 Budapest Holosui Esch Uzza 25 (72) Inventor Lathrow Barrage Hungary 1088 Budapest Budapest Uzza 38 (72) Inventor Imre Doman Hungary Ha-1035 Budapest Mocha チ ュ Uzza 18b (72) Inventor Zoltan Ratkai Har-1101 Budapest Monoli Uzza, Hungary 19 (72) Inventor Peter Selesh Hungary 1153 Budapest Reda Barnen Uzza 6 (72) Inventor Ferenc Barta Hungary Har-4440 Tisavasi vari Kaba バ イ u Uzza 3-5 / 5 Inventor Jorzey Veletskeine Donat Hungary Har-1036 Budapest Layosh Uzza 49be (72) Inventor Karman Naj Hungary Har-1025 Budapest Turishta Uzza 2A F-term (reference) 4C022 GA07
Claims (17)
)−2,2−ジメチル−1,3−ジオキサン−4−アセテートの塩。1. A compound of the general formula (I) formed by an organic acid (4R-cis)-(1,1-dimethyl-ethyl) -6- (2-aminoethyl
) -2,2-Dimethyl-1,3-dioxane-4-acetate salt.
シクロアルカンカルボン酸、脂肪族不飽和カルボン酸、芳香族カルボン酸、複素
環式カルボン酸又はスルホン酸によって形成されたものである請求項1記載の一
般式(I)で表される化合物の塩。2. An aliphatic monocarboxylic acid, dicarboxylic acid or polycarboxylic acid,
The salt of the compound represented by the formula (I) according to claim 1, which is formed by a cycloalkanecarboxylic acid, an aliphatic unsaturated carboxylic acid, an aromatic carboxylic acid, a heterocyclic carboxylic acid or a sulfonic acid.
ンゴ酸、コハク酸、マロン酸、クエン酸、シクロプロパンカルボン酸、シクロブ
タンカルボン酸、シクロペンタンカルボン酸、シクロヘキサンカルボン酸、フマ
ル酸、マレイン酸、安息香酸、m−メチル−安息香酸、4−メトキシ−安息香酸
、4−ブロモ−安息香酸、4−第3級ブチル−安息香酸、ベンゼンスルホン酸、
メタンスルホン酸、p−メチル−ベンゼンスルホン酸、p−ブロモ−ベンゼンス
ルホン酸、ニコチン酸、テトラヒドロフラン−2−カルボン酸又はチオフェン−
3−カルボン酸によって形成されたものである請求項2記載の一般式(I)で表
される化合物の塩。3. Acetic acid, butyric acid, valeric acid, isovaleric acid, pivalic acid, oxalic acid, malic acid, succinic acid, malonic acid, citric acid, cyclopropanecarboxylic acid, cyclobutanecarboxylic acid, cyclopentanecarboxylic acid, cyclohexanecarboxylic acid Acid, fumaric acid, maleic acid, benzoic acid, m-methyl-benzoic acid, 4-methoxy-benzoic acid, 4-bromo-benzoic acid, 4-tert-butyl-benzoic acid, benzenesulfonic acid,
Methanesulfonic acid, p-methyl-benzenesulfonic acid, p-bromo-benzenesulfonic acid, nicotinic acid, tetrahydrofuran-2-carboxylic acid or thiophene-
The salt of the compound represented by the formula (I) according to claim 2, which is formed by 3-carboxylic acid.
式(I)で表される化合物の塩。4. The salt of the compound represented by the general formula (I) according to claim 1, which is formed by pivalic acid.
エチル)−6−(2−アミノエチル)−2,2−ジメチル−1,3−ジオキサン−4
−アセテートの塩を製造する方法において、一般式(I)で表される(4R−シ
ス)−(1,1−ジメチル−エチル)−6−(2−アミノエチル)−2,2−ジメチル
−1,3−ジオキサン−4−アセテートを、有機溶媒中で、有機酸と反応させる
ことを特徴とする塩の製法。5. The (4R-cis)-(1,1-dimethyl-) represented by the general formula (I)
Ethyl) -6- (2-aminoethyl) -2,2-dimethyl-1,3-dioxane-4
In a method for producing an acetate salt, (4R-cis)-(1,1-dimethyl-ethyl) -6- (2-aminoethyl) -2,2-dimethyl- represented by the general formula (I) A method for producing a salt, comprising reacting 1,3-dioxane-4-acetate with an organic acid in an organic solvent.
リカルボン酸、シクロアルカンカルボン酸、脂肪族不飽和カルボン酸、芳香族カ
ルボン酸、複素環式カルボン酸又はスルホン酸を使用することを特徴とする請求
項5記載の製法。6. As the organic acid, an aliphatic monocarboxylic acid, dicarboxylic acid or polycarboxylic acid, cycloalkanecarboxylic acid, aliphatic unsaturated carboxylic acid, aromatic carboxylic acid, heterocyclic carboxylic acid or sulfonic acid is used. The method according to claim 5, wherein:
ンゴ酸、コハク酸、マロン酸、クエン酸、シクロプロパンカルボン酸、シクロブ
タンカルボン酸、シクロペンタンカルボン酸、シクロヘキサンカルボン酸、フマ
ル酸、マレイン酸、安息香酸、m−メチル−安息香酸、4−メトキシ−安息香酸
、4−ブロモ−安息香酸、4−第3級ブチル−安息香酸、ベンゼンスルホン酸、
メタンスルホン酸、p−メチル−ベンゼンスルホン酸、p−ブロモ−ベンゼンス
ルホン酸、ニコチン酸、テトラヒドロフラン−2−カルボン酸又はチオフェン−
3−カルボン酸を使用することを特徴とする請求項6記載の製法。7. Acetic acid, butyric acid, valeric acid, isovaleric acid, pivalic acid, oxalic acid, malic acid, succinic acid, malonic acid, citric acid, cyclopropanecarboxylic acid, cyclobutanecarboxylic acid, cyclopentanecarboxylic acid, cyclohexanecarboxylic acid Acid, fumaric acid, maleic acid, benzoic acid, m-methyl-benzoic acid, 4-methoxy-benzoic acid, 4-bromo-benzoic acid, 4-tert-butyl-benzoic acid, benzenesulfonic acid,
Methanesulfonic acid, p-methyl-benzenesulfonic acid, p-bromo-benzenesulfonic acid, nicotinic acid, tetrahydrofuran-2-carboxylic acid or thiophene-
7. The method according to claim 6, wherein a 3-carboxylic acid is used.
性の溶媒を使用することを特徴とする請求項6〜8のいずれかに記載の製法。9. The process according to claim 6, wherein a nonpolar, polar, aprotic or protic solvent is used as the reaction medium.
ゲン化炭化水素、エステル、ニトリル、アルコール又はエーテルを使用すること
を特徴とする請求項9記載の製法。10. The method according to claim 9, wherein an aliphatic hydrocarbon, an aromatic hydrocarbon, a halogenated hydrocarbon, an ester, a nitrile, an alcohol or an ether is used as the organic solvent.
ルエン、ベンゼン、キシレン、ジクロロメタン、クロロホルム、酢酸エチル、ア
セトニトリル、メタノール、エタノール、イソプロパノール、テトラヒドロフラ
ン、ジオキサン又はジエチルエーテルを使用することを特徴とする請求項10記
載の製法。11. An organic solvent comprising hexane, heptane, petroleum ether, toluene, benzene, xylene, dichloromethane, chloroform, ethyl acetate, acetonitrile, methanol, ethanol, isopropanol, tetrahydrofuran, dioxane or diethyl ether. The method according to claim 10, wherein
求項9〜11のいずれかに記載の製法。12. The process according to claim 9, wherein a solvent mixture is used as a reaction medium.
ン、ヘキサン−トルエン−テトラヒドロフラン、ヘプタン−トルエン−テトラヒ
ドロフラン、又はヘキサン−ジエチルエーテルの混合物を使用することを特徴と
する請求項12記載の製法。13. The method according to claim 12, wherein a mixture of heptane-toluene, hexane-toluene, hexane-toluene-tetrahydrofuran, heptane-toluene-tetrahydrofuran, or hexane-diethyl ether is used as a reaction medium. .
に溶解させ、2つの溶液を混合することを特徴とする請求項5〜13のいずれか
に記載の製法。14. The process according to claim 5, wherein the compound represented by the general formula (I) and the organic acid are dissolved in the same solvent, and the two solutions are mixed. .
、好ましくは0.5〜2、特に好ましくは0.5〜1.2のモル比で使用すること
を特徴とする請求項5〜13のいずれかに記載の製法。15. A compound represented by the general formula (I) and an organic acid,
The process according to any of claims 5 to 13, characterized in that it is used in a molar ratio of preferably 0.5 to 2, particularly preferably 0.5 to 1.2.
ことを特徴とする請求項5〜15のいずれかに記載の製法。16. The process according to claim 5, wherein the reaction is carried out at room temperature or under heating, preferably at 20 to 90 ° C.
−エチル)−6−(2−アミノエチル)−2,2−ジメチル−1,3−ジオキサン−
4−アセテートを使用することを特徴とする請求項5〜16のいずれかに記載の
製法。17. A raw material comprising crude (4R-cis)-(1,1-dimethyl-ethyl) -6- (2-aminoethyl) -2,2-dimethyl-1,3-dioxane-
The method according to any one of claims 5 to 16, wherein 4-acetate is used.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HU9901526A HU227840B1 (en) | 1999-05-06 | 1999-05-06 | Intermediates of atorvastatin synthesis and process for producing them |
HU9901526 | 1999-05-06 | ||
PCT/HU2000/000042 WO2000068221A1 (en) | 1999-05-06 | 2000-05-05 | Salts of 2,2-dimethyl-1,3-dioxane intermediates and process for the preparation thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2002544207A true JP2002544207A (en) | 2002-12-24 |
Family
ID=89998261
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2000617201A Pending JP2002544207A (en) | 1999-05-06 | 2000-05-05 | 2,2-Dimethyl-1,3-dioxane intermediate salt and method for producing the same |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP1178980A1 (en) |
JP (1) | JP2002544207A (en) |
KR (1) | KR20020033617A (en) |
CN (1) | CN1349522A (en) |
AU (1) | AU4600200A (en) |
CA (1) | CA2373077A1 (en) |
CZ (1) | CZ20013965A3 (en) |
HK (1) | HK1046271A1 (en) |
HR (1) | HRP20010846A2 (en) |
HU (1) | HU227840B1 (en) |
PL (1) | PL351145A1 (en) |
RU (1) | RU2001133066A (en) |
SK (1) | SK15842001A3 (en) |
WO (1) | WO2000068221A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007034909A1 (en) * | 2005-09-22 | 2007-03-29 | Kaneka Corporation | Process for production of (3r,5r)-7-amino-3,5-dihydroxyheptanoic acid derivative |
US10676441B2 (en) | 2015-08-05 | 2020-06-09 | Api Corporation | Method for producing pitavastatin calcium |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0011120D0 (en) | 2000-05-09 | 2000-06-28 | Avecia Ltd | Process |
NL1015744C2 (en) | 2000-07-19 | 2002-01-22 | Dsm Nv | Process for the preparation of 2- (6-substituted-1,3-dioxan-4-yl) acetic acid derivatives. |
WO2002057229A1 (en) * | 2001-01-19 | 2002-07-25 | Biocon India Limited | FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN) |
CA2451159A1 (en) | 2001-07-06 | 2003-01-16 | Teva Pharmaceutical Industries Ltd. | Process for the preparation of 7-amino syn 3,5-dihydroxy heptanoic acid derivatives via 6-cyano syn 3,5-dihydroxy hexanoic acid derivatives |
EP1323717A1 (en) | 2001-12-27 | 2003-07-02 | Dsm N.V. | Process for the preparation of 2-(6-Substituted-1,3-Dioxane-4-yL) acetic acid derivatives |
EP1375493A1 (en) * | 2002-06-17 | 2004-01-02 | Dsm N.V. | Process for the preparation of an dioxane acetic acid ester |
ATE509009T1 (en) | 2005-03-14 | 2011-05-15 | C P Pharmaceuticals Internat C V | PREPARATION OF ATORVASTATIN INTERMEDIATE USING PAAL-KNORR CONDENSATION |
WO2012032035A1 (en) | 2010-09-09 | 2012-03-15 | Dsm Sinochem Pharmaceuticals Netherlands B.V. | Salts of 7-amino-3,5-dihydroxyheptanoic acid esters |
CN108191813B (en) * | 2017-12-20 | 2020-01-17 | 帕潘纳(北京)科技有限公司 | Preparation method of ketal |
CN109232353A (en) * | 2018-10-09 | 2019-01-18 | 河南师范大学 | A kind of preparation method of Atorvastatin calcium condensation product |
CN109232354A (en) * | 2018-10-09 | 2019-01-18 | 河南师范大学 | A kind of preparation method of high purity atorvastatin calcium raw material drug |
CN110940764B (en) * | 2019-12-31 | 2022-06-28 | 湖南九典制药股份有限公司 | Separation method of statin optical isomer |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5003080A (en) * | 1988-02-22 | 1991-03-26 | Warner-Lambert Company | Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis |
US5103024A (en) * | 1990-10-17 | 1992-04-07 | Warner-Lambert Company | Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate |
US5155251A (en) * | 1991-10-11 | 1992-10-13 | Warner-Lambert Company | Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate |
US5278313A (en) * | 1992-03-27 | 1994-01-11 | E. R. Squibb & Sons, Inc. | Process for the preparation of 1,3-dioxane derivatives useful in the preparation of HMG-COA reductase inhibitors |
JP3652394B2 (en) * | 1995-01-27 | 2005-05-25 | 高砂香料工業株式会社 | N-substituted-7-amino-5-hydroxy-3-oxoheptanoic acid derivative and process for producing the same |
CN1093126C (en) * | 1996-07-29 | 2002-10-23 | 沃尼尔·朗伯公司 | Improved process for the synthesis of protected esters of (s)-3,4-dihydroxytubyric acid |
HUP0103659A3 (en) * | 1998-04-30 | 2003-01-28 | Kaneka Corp | Process for producing 6-cyanomethyl-1,3-dioxane-4-acetic acid derivatives |
-
1999
- 1999-05-06 HU HU9901526A patent/HU227840B1/en not_active IP Right Cessation
-
2000
- 2000-05-05 JP JP2000617201A patent/JP2002544207A/en active Pending
- 2000-05-05 KR KR1020017014104A patent/KR20020033617A/en not_active Application Discontinuation
- 2000-05-05 CZ CZ20013965A patent/CZ20013965A3/en unknown
- 2000-05-05 SK SK1584-2001A patent/SK15842001A3/en unknown
- 2000-05-05 RU RU2001133066/04A patent/RU2001133066A/en unknown
- 2000-05-05 WO PCT/HU2000/000042 patent/WO2000068221A1/en active Search and Examination
- 2000-05-05 EP EP00927612A patent/EP1178980A1/en not_active Withdrawn
- 2000-05-05 PL PL00351145A patent/PL351145A1/en unknown
- 2000-05-05 CN CN00807159A patent/CN1349522A/en active Pending
- 2000-05-05 CA CA002373077A patent/CA2373077A1/en not_active Abandoned
- 2000-05-05 AU AU46002/00A patent/AU4600200A/en not_active Abandoned
-
2001
- 2001-11-16 HR HR20010846A patent/HRP20010846A2/en not_active Application Discontinuation
-
2002
- 2002-08-06 HK HK02105736.6A patent/HK1046271A1/en unknown
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007034909A1 (en) * | 2005-09-22 | 2007-03-29 | Kaneka Corporation | Process for production of (3r,5r)-7-amino-3,5-dihydroxyheptanoic acid derivative |
US10676441B2 (en) | 2015-08-05 | 2020-06-09 | Api Corporation | Method for producing pitavastatin calcium |
US10815201B2 (en) | 2015-08-05 | 2020-10-27 | Api Corporation | Method for producing pitavastatin calcium |
Also Published As
Publication number | Publication date |
---|---|
WO2000068221A1 (en) | 2000-11-16 |
SK15842001A3 (en) | 2002-04-04 |
CZ20013965A3 (en) | 2002-04-17 |
HK1046271A1 (en) | 2003-01-03 |
CA2373077A1 (en) | 2000-11-16 |
HRP20010846A2 (en) | 2003-02-28 |
PL351145A1 (en) | 2003-03-24 |
HU9901526D0 (en) | 1999-07-28 |
HU227840B1 (en) | 2012-05-02 |
EP1178980A1 (en) | 2002-02-13 |
RU2001133066A (en) | 2004-02-27 |
HUP9901526A2 (en) | 2001-04-28 |
AU4600200A (en) | 2000-11-21 |
KR20020033617A (en) | 2002-05-07 |
CN1349522A (en) | 2002-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100463614B1 (en) | Process to Prepare Tolterodine | |
EP2145882B1 (en) | Process for obtaining olopatadine and intermediates | |
JP2002544207A (en) | 2,2-Dimethyl-1,3-dioxane intermediate salt and method for producing the same | |
JPH07215921A (en) | Production of pest control agent and intermediate | |
JPH08119968A (en) | Production of condensed pyridine compounds | |
RU2094428C1 (en) | Method of synthesis of benzopyrane compounds, intermediate compounds and methods of their synthesis | |
JP2003506425A (en) | Method for producing nitroxyalkyl ester of naproxen | |
US20080287693A1 (en) | Process for the Preparation of 1-Naphthol Mixed Ethers and Intermediates of Crystalline Forms of (+) and (-)-Duloxetine | |
US6538134B2 (en) | 4-Benzyl-2-hydroxy-1,4-oxazine-3-one and polymorphic forms thereof | |
EP1611084A1 (en) | Process for the manufacture of n-alkoxalyl-alaninates | |
JPH02289563A (en) | Improved process for producing ortho-carboxypyridyl- and ortho-carboxyquinolylimidazolinones | |
JP2769058B2 (en) | Preparation of cyclopropane derivatives | |
JPH072733A (en) | Production of benzoic acid and nicotinic acid derivative | |
JP2003515600A (en) | Process for producing {2- [4- (α-phenyl-p-chlorobenzyl) piperazin-1-yl] ethoxy} acetic acid and novel intermediates therefor | |
JP3533567B2 (en) | A new synthetic method to produce substituted quinolines from substituted anilines | |
US6426417B1 (en) | Processes and intermediates useful to make antifolates | |
WO2010000193A1 (en) | Preparation of osemozotan and its pharmaceutically acceptable salts, and its intermediate | |
JP2002512210A (en) | Method for producing 2-hydroxyalkylhalophenone | |
JPH07233164A (en) | Preparation of pilocarpine derivative | |
JP3144921B2 (en) | Benzyl ester derivative and method for producing the same | |
JP3144920B2 (en) | α-Acylaminoketone derivatives, production method thereof and use thereof | |
JPH11240869A (en) | Lactam carboxylic acid derivative, its production and production of piperidine derivative using the same | |
JPH0576473B2 (en) | ||
JP3037399B2 (en) | Preparation of imidazole derivatives | |
JPH07291957A (en) | Method and intermediate for producing 5-oxaspiro(2.4)hetan-6-one |